Proton Pump Inhibitor (PPI) sebagai Farmakoterapi GERD pada Lansia

Authors

  • Josephine Herwita Atepela Dokter Umum, Jakarta

DOI:

https://doi.org/10.55175/cdk.v50i7.635

Keywords:

Gastroesophageal reflux disease, lansia, proton pump inhibitor

Abstract

Gastroesophageal reflux disease (GERD) merupakan salah satu penyakit gastrointestinal (GI) paling umum pada lanjut usia (lansia). Gejala GERD pada lansia umumnya atipikal dan tidak terlalu parah, namun lebih berisiko terjadi kelainan mukosa dan komplikasi. Proton pump inhibitor (PPI) masih menjadi sarana farmakoterapi terapi lini pertama pasien GERD lansia. Namun, penggunaan PPI pada lansia dikaitkan dengan beberapa efek samping. Hingga saat ini, belum ada konsensus mengenai durasi optimal penggunaan PPI pada lansia.

 

Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal (GI) diseases in the elderly. GERD symptoms in the elderly are generally atypical and less severe, but with a higher risk of mucosal abnormalities and complications. Proton pump inhibitor (PPI) therapy is still the first line pharmacotherapy for elderly GERD patients. However, PPI use in elderly are associated with several side effects. To date, there is no consensus yet on the optimal duration of PPI use in the elderly.

Downloads

Download data is not yet available.

References

Piper MS, Hall KE. Gastroenterology. Geriatrics for specialists. 2021:279-80. https://doi.org/10.1007/978-3-030-76271-1_21

Kurin M, Fass R. Management of gastroesophageal reflux disease in the elderly patient. Drugs & Aging. 2019;36(12):1073–81. https://doi.org/10.1007/s40266-019-00708-2

Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–56. DOI:10.1016/s0016-5085(97)70025-8

Notariza KR, Nurcholis, Yusaryahya H, Karimah NS, Mansur AY, Adhiguna G, et al. Gastroesophageal reflux disease among elderly type 2 diabetes mellitus in a rural area of Central Sulawesi: A cross-sectional study. Acta Medica Indon. 2021;53(1):42-51.

Ahmed A, Clarke JO. Proton pump inhibitors (PPI). StatPearls [Internet]. 2021 [cited 2023 Feb 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557385/

Pilotto A, Leandro G, Franceschi M. Short- and long-term therapy for reflux oesophagitis in the elderly: A multi-centre, placebo-controlled study with pantoprazole. Alimentary Pharmacol Therapeutics. 2003;17(11):1399–406. DOI:10.1046/j.1365-2036.2003.01593.x

James OFW, Parry-billings KS. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis. Age Ageing. 1994;23(2):121–6. DOI: 10.1093/ageing/23.2.121

Hasselgren G, Hassan-Alin M, Andersson T, Claar-Nilsson C, Röhss K. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinetics. 2001;40(2):145–50. DOI: 10.2165/00003088-200140020-00006

Lin SF, Lin PC, Chang CC, Chang WL, Chu FY. Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay. Medicine. 2020;99(50):e23695. DOI: 10.1097/MD.0000000000023695

Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. DOI:10.1053/j.gastro.2017.01.031

Wu CY, Xiong LY, Ouk M, Rabin JS, Herrmann N, Lanctôt KL, et al. Gastric acid suppressants and cognitive decline in people with or without cognitive impairment. Alzheimer's Dementia: Translational Res Clin Interventions. 2022;8(1). DOI: 10.1002/trc2.12243

Chen LY, Lin HJ, Wu WT, Chen YC, Chen CL, Kao J, et al. Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Internat J Environment Res Publ Health. 2020;17(21):8271. DOI:10.3390/ijerph17218271

Thong BK, Ima-Nirwana S, Chin K-Y. Proton Pump Inhibitors and Fracture Risk: A review of current evidence and mechanisms involved. Internat Environment Res Publ Health. 2019;16(9):1571. DOI:10.3390/ijerph16091571

Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Therapeutic Advances in Drug Safety. 2017;8(9):273–97. DOI: https://doi.org/10.1177/2042098617715381

Mafi JN, May FP, Kahn KL, Chong M, Corona E, Yang L, et al. Low‐value proton pump inhibitor prescriptions among older adults at a large academic health system. J Am Geriatr Soc. 2019;67(12):2600–4. DOI: 10.1111/jgs.16117

Boustani M, Hall KS, Lane KA, Aljadhey H, Gao S, Unverzagt F, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. Journal of the American Geriatrics Society. 2007;55(8):1248–53. DOI: https://doi.org/10.1111/j.1532-5415.2007.01270.x

Downloads

Published

03-07-2023

How to Cite

Atepela, J. H. (2023). Proton Pump Inhibitor (PPI) sebagai Farmakoterapi GERD pada Lansia. Cermin Dunia Kedokteran, 50(7), 379–382. https://doi.org/10.55175/cdk.v50i7.635